Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.
Gary Landreth, PhD
A Randomized Controlled Study to Evaluate the Effect of Bexarotene, an RXR Agonist, on beta-Amyloid and Apolipoprotein E Metabolism in Healthy Subjects
A GuideStar-Rated Charity
© Copyright 2026. The Alzheimer's Drug Discovery Foundation, a not-for-profit, section 501 (c)(3).